Head-To-Head Comparison: Zicix (OTCMKTS:ZICXD) vs. COMPASS Pathways (NASDAQ:CMPS)

Zicix (OTCMKTS:ZICXD) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Volatility & Risk

Zicix has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.

Valuation & Earnings

This table compares Zicix and COMPASS Pathways”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zicix	N/A	N/A	N/A	($100.14)	-0.03
COMPASS Pathways	N/A	N/A	-$155.12 million	($2.72)	-2.34

COMPASS Pathways is trading at a lower price-to-earnings ratio than Zicix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Zicix and COMPASS Pathways, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zicix	0	0	0	0	0.00
COMPASS Pathways	1	1	7	0	2.67

COMPASS Pathways has a consensus price target of $15.88, suggesting a potential upside of 149.61%. Given COMPASS Pathways’ stronger consensus rating and higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Zicix.

Institutional & Insider Ownership

46.2% of COMPASS Pathways shares are held by institutional investors. 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Zicix and COMPASS Pathways’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zicix	N/A	N/A	N/A
COMPASS Pathways	N/A	-111.18%	-56.55%

Summary

COMPASS Pathways beats Zicix on 7 of the 10 factors compared between the two stocks.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.